Johnny Mahlangu to Blood Coagulation Factors
This is a "connection" page, showing publications Johnny Mahlangu has written about Blood Coagulation Factors.
Connection Strength
1,865
-
Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. BioDrugs. 2018 Dec; 32(6):561-570.
Score: 0,634
-
Guideline for the treatment of haemophilia in South Africa. S Afr Med J. 2008 Feb; 98(2 Pt 2):126-40.
Score: 0,299
-
Diagnosis and treatment challenges in lower resource countries: State-of-the-art. Haemophilia. 2024 Apr; 30 Suppl 3:78-85.
Score: 0,229
-
Prophylaxis is the new standard of care in patients with haemophilia. S Afr Med J. 2022 05 31; 112(6):405-408.
Score: 0,202
-
Emicizumab state-of-the-art update. Haemophilia. 2022 May; 28 Suppl 4:103-110.
Score: 0,201
-
Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016 Nov; 22(6):866-872.
Score: 0,134
-
Guidelines for the management of hemophilia. Haemophilia. 2013 Jan; 19(1):e1-47.
Score: 0,102
-
Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818.
Score: 0,036
-
Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014 Jan; 12 Suppl 1:s319-29.
Score: 0,028